MBX Biosciences (MBX) Enterprise Value (2023 - 2026)

MBX Biosciences has disclosed Enterprise Value across 4 years of filings, most recently posting -$440.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$440.0 million, down 82.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$440.0 million (down 82.73% YoY), and the FY2025 annual result was -$373.7 million, down 42.55% from the prior year.
• Enterprise Value came in at -$440.0 million for Q1 2026 at MBX Biosciences, down from -$373.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $115.9 million in Q3 2023 to a low of -$440.0 million in Q1 2026.
• The 4-year median for Enterprise Value is -$240.8 million (2025), against an average of -$180.6 million.
• Across the five-year window, Enterprise Value tumbled 845.16% in 2024 and plunged 41.37% in 2025, its largest moves.
• MBX Biosciences' Enterprise Value stood at $35.2 million in 2023, then sank by 845.16% to -$262.1 million in 2024, then tumbled by 42.55% to -$373.7 million in 2025, then declined by 17.73% to -$440.0 million in 2026.
• The last three Enterprise Value figures came in at -$440.0 million (Q1 2026), -$373.7 million (Q4 2025), and -$391.7 million (Q3 2025), per Business Quant data.